How glucagon-like peptide 1 receptor agonists work

In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreasen, Christine Rode, Andersen, Andreas, Knop, Filip Krag, Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346189/
https://www.ncbi.nlm.nih.gov/pubmed/34137731
http://dx.doi.org/10.1530/EC-21-0130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346189/
https://www.ncbi.nlm.nih.gov/pubmed/34137731
http://dx.doi.org/10.1530/EC-21-0130

Ejemplares similares